Adaptive Biotechnologies Q3 revenue falls 11% to $83.9 million; MRD guidance raised
Adaptive Biotechnologies reported third quarter 2026 revenue of $83.9 million, down 11% from the prior-year quarter, and net income attributable to the company of $2.9 million, or $0.02 per share, compared with $9.5 million, or $0.06 per share, a year earlier. The company raised its full-year 2026 MRD revenue guidance to $276 million to $286 million, while MRD revenue grew 28% in the quarter. Shareholders face lower reported revenue and profit this quarter, offset by the higher MRD outlook.
Key points
- Q3 2026 revenue was $83.9 million, down 11% from $94.0 million in Q3 2025; MRD revenue rose 28% to $72.6 million
- Net income attributable to Adaptive was $2.9 million ($0.02 per share), versus $9.5 million ($0.06 per share) in Q3 2025
- Full-year 2026 MRD revenue guidance raised to $276 million to $286 million, from $268 million to $278 million
- Total company operating expenses expected at approximately $350 million, versus the prior range of $350 million to $355 million
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.